Vella Bioscience Secures $7M Seed II
LOS ANGELES, CA, Vella Bioscience has closed a $7 million seed II funding round.
Vella Bioscience, the femtech company behind Vella Women's Pleasure Serum, a first-of-its-kind, clinically demonstrated pre-play topical serum that promotes increased arousal and lubrication, and more frequent, intense, and satisfying orgasms, has closed a $7 million seed II funding round, anchored by Aaron Fleck & Associates.
The funding round, which was heavily oversubscribed, puts Vella Bioscience, Inc. at over $50 million post-money valuation, positioning the femtech company to move forward on its mission in putting science in service of every woman's sexual empowerment.
Vella Bioscience, Inc. is a femtech company driven to put science in service of every woman's sexual empowerment. At the company's core, women come first. Founded by a team of medical researchers, scientists and industry experts, Vella Bioscience, Inc. leads the intersection of proprietary science and luxury beauty for sexual wellness. Vella Bioscience, Inc. launched with its flagship, category-first product, Vella Pleasure Serum, which is designed to give women power over their pleasure. The first-of-its-kind serum features proprietary nano-encapsulated CBD technology, which serves as the company's platform technology to advance a product portfolio of radical innovations further strengthening the promise of sexual empowerment for all women.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about